ASH 2018

American Society of Hematology (ASH) Annual Meeting and Exposition

San Diego, 1–4 December 2018

Breaking news in hematology-oncology

The American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, was held on the 1–4 December.

Explore the news from big trials, updates from key pivotal studies, exciting discoveries in disease biology, as well as the latest CAR T-cell data and MRD insights, and late-breaking abstracts.

View all videos

CLL

Venetoclax and bendamustine plus rituximab or obinutuzumab for CLL

Stephan Stilgenbauer

Ibrutinib emerging as the new standard of care for frontline elderly CLL: ALLIANCE results

Jennifer Woyach

Multiple Myeloma

Quadruplet regimens for newly diagnosed myeloma & MRD-tracking of DKRd-treated patients

Ixazomib prolongs PFS following ASCT in newly diagnosed myeloma

Vincent Rajkumar

Waldenström’s

Association between depth of response and survival in Waldenström’s

Mass spectrometry-flow cytometry study of IgM MGUS progression to Waldenström’s

AML

An update on AMG 330: can BiTEs be as successful in AML as ALL?

Marion Subklewe

E-selectin antagonist uproleselan for R/R AML: efficacy and safety data

Daniel DeAngelo

Lymphoma

Updated JULIET results for tisagenlecleucel in DLBCL

Richard Thomas Maziarz

R2 in the second-line: lenalidomide-rituximab improves PFS in relapsed/refractory NHL

ALL

Initial data for CAR T-cell product JCAR021 in ALL and B-cell lymphoma

Jordan Gauthier

Updated pivotal ELIANA study results for CAR T-cell product tisagenlecleucel in ALL

Sickle Cell Disease & β-Thalassemia

BELIEVE: β-thalassemia treatment with luspatercept reduces transfusion burden

Maria Domenica Cappellini

Opioid use in sickle cell is not associated with in-hospital mortality in the US

Oladimeji Akinola Akinboro

Trial Updates

Updates from MURANO for CLL: time-limited VenR & impact of MRD

Reduced R-CHOP in favourable-prognosis DLBCL doesn’t compromise outlook